Clinical Trial Update: Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of daclatasvir (BMS-790052) plus pegylated interferon alfa-2b and ribavirin in Japanese patients with hepatitis C; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Daclatasvir (daclatasvir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C Infection | Phase 2 | Status: COMPLETED | Results posted: 2015-10-12